France’s Innate Pharma has signed a deal to pay Novo Nordisk $2.7 million up front and as much as $27 million in milestones for exclusive rights to the pair’s Phase II-ready cancer immunotherapy.

…read more

Source: Innate goes it alone on a cancer drug, buying out Novo for up to $30M


0 No comments